Anacor wins big in dermatitis market of many millions
This article was originally published in Scrip
Anacor Pharmaceuticals jumped 55.9% to close at $131.93 per share on 13 July on positive top-line Phase III results for the atopic dermatitis (AD) drug crisaborole, which could be safer than other topical treatments for millions of patients – mostly children – with mild-to-moderate forms of the skin disease.
You may also be interested in...
UK biotech Ziarco’s orally active histamine H4-antagonist shows potential in atopic dermatitis in proof-of-concept studies, and the firm may seek capital for further studies before it is Phase III ready.
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.
CEO Amit Munshi told the J.P. Morgan meeting the company will double the size of its clinical-stage cardiovascular disease pipeline with the addition of temanogrel.